QQQ   419.50 (-0.92%)
AAPL   165.35 (-1.01%)
MSFT   402.38 (-0.47%)
META   489.14 (-2.52%)
GOOGL   154.97 (-0.67%)
AMZN   176.30 (-1.63%)
TSLA   150.47 (+0.36%)
NVDA   824.90 (-2.58%)
AMD   150.72 (-2.81%)
NIO   3.87 (-3.25%)
BABA   68.87 (-0.01%)
T   16.31 (-0.12%)
F   12.14 (+0.66%)
MU   108.74 (-2.85%)
GE   151.21 (-1.13%)
CGC   7.85 (+0.26%)
DIS   111.89 (-0.48%)
AMC   3.12 (+6.85%)
PFE   25.69 (+1.18%)
PYPL   62.09 (-0.02%)
XOM   120.55 (+1.71%)
QQQ   419.50 (-0.92%)
AAPL   165.35 (-1.01%)
MSFT   402.38 (-0.47%)
META   489.14 (-2.52%)
GOOGL   154.97 (-0.67%)
AMZN   176.30 (-1.63%)
TSLA   150.47 (+0.36%)
NVDA   824.90 (-2.58%)
AMD   150.72 (-2.81%)
NIO   3.87 (-3.25%)
BABA   68.87 (-0.01%)
T   16.31 (-0.12%)
F   12.14 (+0.66%)
MU   108.74 (-2.85%)
GE   151.21 (-1.13%)
CGC   7.85 (+0.26%)
DIS   111.89 (-0.48%)
AMC   3.12 (+6.85%)
PFE   25.69 (+1.18%)
PYPL   62.09 (-0.02%)
XOM   120.55 (+1.71%)
QQQ   419.50 (-0.92%)
AAPL   165.35 (-1.01%)
MSFT   402.38 (-0.47%)
META   489.14 (-2.52%)
GOOGL   154.97 (-0.67%)
AMZN   176.30 (-1.63%)
TSLA   150.47 (+0.36%)
NVDA   824.90 (-2.58%)
AMD   150.72 (-2.81%)
NIO   3.87 (-3.25%)
BABA   68.87 (-0.01%)
T   16.31 (-0.12%)
F   12.14 (+0.66%)
MU   108.74 (-2.85%)
GE   151.21 (-1.13%)
CGC   7.85 (+0.26%)
DIS   111.89 (-0.48%)
AMC   3.12 (+6.85%)
PFE   25.69 (+1.18%)
PYPL   62.09 (-0.02%)
XOM   120.55 (+1.71%)
QQQ   419.50 (-0.92%)
AAPL   165.35 (-1.01%)
MSFT   402.38 (-0.47%)
META   489.14 (-2.52%)
GOOGL   154.97 (-0.67%)
AMZN   176.30 (-1.63%)
TSLA   150.47 (+0.36%)
NVDA   824.90 (-2.58%)
AMD   150.72 (-2.81%)
NIO   3.87 (-3.25%)
BABA   68.87 (-0.01%)
T   16.31 (-0.12%)
F   12.14 (+0.66%)
MU   108.74 (-2.85%)
GE   151.21 (-1.13%)
CGC   7.85 (+0.26%)
DIS   111.89 (-0.48%)
AMC   3.12 (+6.85%)
PFE   25.69 (+1.18%)
PYPL   62.09 (-0.02%)
XOM   120.55 (+1.71%)
NASDAQ:PCVX

Vaxcyte (PCVX) Stock Price, News & Analysis

$60.47
-0.15 (-0.25%)
(As of 11:04 AM ET)
Today's Range
$60.02
$61.92
50-Day Range
$60.62
$81.05
52-Week Range
$41.57
$82.04
Volume
216,224 shs
Average Volume
823,491 shs
Market Capitalization
$6.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.50

Vaxcyte MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
27.5% Upside
$78.50 Price Target
Short Interest
Bearish
7.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Vaxcyte in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$6.94 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.18) to ($4.51) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.15 out of 5 stars

Medical Sector

763rd out of 918 stocks

Biological Products, Except Diagnostic Industry

133rd out of 154 stocks

PCVX stock logo

About Vaxcyte Stock (NASDAQ:PCVX)

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

PCVX Stock Price History

PCVX Stock News Headlines

New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
PCVX Jul 2024 70.000 put
PCVX Apr 2024 80.000 put
PCVX Apr 2024 100.000 call
TD Cowen Remains a Buy on Vaxcyte (PCVX)
Vaxcyte Stock (NASDAQ:PCVX), Short Interest Report
5 Best Russell 2000 Stocks To Buy According To Hedge Funds
PCVX Apr 2024 50.000 call
PCVX Sep 2024 40.000 put
PCVX Mar 2024 90.000 call
See More Headlines
Receive PCVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/19/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PCVX
Fax
N/A
Employees
254
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$78.50
High Stock Price Target
$95.00
Low Stock Price Target
$69.00
Potential Upside/Downside
+29.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-402,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$13.04 per share

Miscellaneous

Free Float
104,505,000
Market Cap
$6.59 billion
Optionable
Optionable
Beta
0.89
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Grant E. Pickering M.B.A. (Age 56)
    Co-Founder, CEO & Director
    Comp: $1.1M
  • Mr. Andrew L. Guggenhime M.B.A. (Age 56)
    President & CFO
    Comp: $839.65k
  • Mr. James Wassil M.B.A.Mr. James Wassil M.B.A. (Age 55)
    M.S., Executive VP & COO
    Comp: $826.3k
  • Mr. Paul W. Sauer M.B.A. (Age 63)
    Senior Vice President of Process Development & Manufacturing
    Comp: $608.96k
  • Dr. Ashish Khanna M.B.A. (Age 52)
    Ph.D., Co-Founder
  • Dr. Jeff Fairman Ph.D. (Age 60)
    Co-Founder & VP of Research
  • Ms. Elvia Cowan (Age 51)
    Senior VP of Finance & Principal Accounting Officer
  • Ms. Janet Graesser
    Senior Vice President of Corporate Communications & Investor Relations
  • Ms. Whitney Jones
    Chief People Officer
  • Mr. Harp Dhaliwal M.B.A. (Age 51)
    Senior Vice President of Commercial Manufacturing & Supply Chain
    Comp: $146.48k

PCVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxcyte stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PCVX shares.
View PCVX analyst ratings
or view top-rated stocks.

What is Vaxcyte's stock price target for 2024?

4 brokerages have issued 1 year price targets for Vaxcyte's stock. Their PCVX share price targets range from $69.00 to $95.00. On average, they predict the company's share price to reach $78.50 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price.
View analysts price targets for PCVX
or view top-rated stocks among Wall Street analysts.

How have PCVX shares performed in 2024?

Vaxcyte's stock was trading at $62.80 on January 1st, 2024. Since then, PCVX shares have decreased by 1.9% and is now trading at $61.59.
View the best growth stocks for 2024 here
.

When is Vaxcyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PCVX earnings forecast
.

How were Vaxcyte's earnings last quarter?

Vaxcyte, Inc. (NASDAQ:PCVX) posted its earnings results on Tuesday, February, 27th. The company reported ($1.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.93. During the same quarter in the previous year, the company earned ($0.73) EPS.

What other stocks do shareholders of Vaxcyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP).

When did Vaxcyte IPO?

Vaxcyte (PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

Who are Vaxcyte's major shareholders?

Vaxcyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.04%) and Banque Cantonale Vaudoise (0.00%). Insiders that own company stock include Andrew Guggenhime, Elvia Cowan, Grant Pickering, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Mikhail Eydelman and Paul Sauer.
View institutional ownership trends
.

How do I buy shares of Vaxcyte?

Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCVX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners